Skip to main content

Table 3 Individual LPV plasma concentrations in patients treated with RBT 150 mg TPW or RBT 300 mg TPW

From: Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

PatientsSexAge (years)Weight (kg)C0 (µg/mL)C1C2C3C4C6C8C12AUC0–12 (µg h/mL)Cl (L/h/kg)CmaxTmax
First group (RBT 150 mg TPW)
 Patient1F3950.511.12.711.54.99.84.719.71109.80.079.84
 Patient3M3656.818.315.321.42013.69.28.910151.30.0521.42
 Patient5M4345.21319.42017.221.71415.216.9203.10.04202
 Patient7M324413.311.711.612.316.423.721.615.7111.80.0823.76
 Patient9F393618.317.719.820.418.817.814.816.1126.50.0920.43
 Patient11F3357.67.5810.310.811.510.78.28.367.40.1111.54
 Patient13M34557.356.268.811.212.28.746.238.161.20.1212.24
 Patient15M245222.123.220.42018.325.723.716.2150.40.0525.76
 Patient17M47606.265.75.8118.39.495.8455.30.12113
Second group (RBT 300 mg TPW)
 Patient2F33400.011.15.613.715.110.29.14.499.50.1015.14
 Patient4M44555.82.353.74.34.12.70.938.40.1952
 Patient6F3340.11.621.824.365.856.877.74.969.90.147.78
 Patient8M3260.8667.26.56.35.754.141.70.167.22
 Patient10F3240.20.018.722.323.919.214.312.87.3104.90.0923.93
 Patient12F2549.212.112.617.813.618.719.515.412.2109.70.0719.56
 Patient14F44526.65.14.424.73.942.71Low25.20.304.73